|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-7-29
|
|
pubmed:abstractText |
Chronic myelogenous leukemia (CML) is a progressive, largely fatal cancer. Emerging treatments may prolong life; however, these result in additional monetary costs. Accurate estimation of their economic impact requires reliable estimates on preferences for health states. The purpose was to estimate preference weights from the general population in four developed countries for standardized health states experienced by persons with CML.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1524-4733
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
103-11
|
|
pubmed:dateRevised |
2010-11-22
|
|
pubmed:meshHeading |
pubmed-meshheading:19659707-Adolescent,
pubmed-meshheading:19659707-Adult,
pubmed-meshheading:19659707-Aged,
pubmed-meshheading:19659707-Cost-Benefit Analysis,
pubmed-meshheading:19659707-Cross-Cultural Comparison,
pubmed-meshheading:19659707-Disease Progression,
pubmed-meshheading:19659707-Female,
pubmed-meshheading:19659707-Humans,
pubmed-meshheading:19659707-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:19659707-Male,
pubmed-meshheading:19659707-Middle Aged,
pubmed-meshheading:19659707-Patient Preference,
pubmed-meshheading:19659707-Quality-Adjusted Life Years,
pubmed-meshheading:19659707-Treatment Outcome,
pubmed-meshheading:19659707-Young Adult
|
|
pubmed:articleTitle |
A multinational study of health state preference values associated with chronic myelogenous leukemia.
|
|
pubmed:affiliation |
Oxford Outcomes Ltd, Vancouver, BC, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
